Partner at Catalio Capital Management
View Live Interactive Profile →Isaac Ro is a Partner at Catalio Capital Management, LP. He holds a B.A. in History with a pre-medical focus from Middlebury College. His firm biography records prior roles as Executive Chairman of Haystack Oncology, Chief Financial Officer of Sema4 and of Thrive Earlier Detection, U.S. medical technology and life science tools equity research lead at Goldman Sachs from 2010 to 2019, the same research role at Leerink Partners, and healthcare investor at Independence Investments. He was appointed to the board of Seer, Inc. (Nasdaq: SEER) on 2 September 2025 and re-elected at the company's annual meeting on 28 July 2026, and is named as a Director of PrognomIQ, Inc. in that issuer's January 2026 Form D. Seer does not appear on his Catalio biography, which lists Pink Dx, PrognomiQ and Visby Medical.